In a report released today, David Lewis from Morgan Stanley maintained a Buy rating on Personalis (PSNL), with a price target of $16.00. The company’s shares closed last Monday at $10.20, close to its 52-week low of $9.65.
According to TipRanks.com, Lewis is a 5-star analyst with an average return of 9.2% and a 68.1% success rate. Lewis covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Edwards Lifesciences, and Intuitive Surgical.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Personalis with a $16.00 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $31.88 and a one-year low of $9.65. Currently, Personalis has an average volume of 277.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Personalis, Inc. provides genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. The company was founded by Euan A. Ashley, Michael Snyder, Atul J. Butte, John S. West, and Russ B. Altman in 2011 and is headquartered in Menlo Park, CA.
